论文部分内容阅读
目的探讨胸腺肽联合抗结核药物治疗复治涂阳肺结核患者的临床疗效。方法回顾性分析2012年1月至2013年12月吉林省结核病骨病医院收治的86例复治涂阳肺结核患者,按随机数字表法将其分为研究组和对照组,各43例。对照组患者给予常规抗结核治疗,同时给予盐酸左氧氟沙星胶囊,研究组患者在对照组基础上皮下注射胸腺肽,比较两组患者的治疗效果、病灶完全吸收率、不良反应发生情况及治疗前后T淋巴细胞亚群。结果研究组患者治疗的总有效率明显高于对照组,差异有统计学意义(P<0.05);研究组患者的病灶完全吸收率明显高于对照组,差异有统计学意义(P<0.05);治疗后,研究组患者CD3+、CD4+、CD4+/CD8+T淋巴细胞亚群百分率均明显高于对照组,CD8+T淋巴细胞亚群百分率明显低于对照组,差异均有统计学意义(均P<0.05)。结论胸腺肽联合抗结核药物治疗复治涂阳肺结核临床疗效明显,能明显改善患者的免疫功能,且不良反应少。
Objective To investigate the clinical efficacy of thymosin combined with anti-tuberculosis drugs in the treatment of relapsed and smear-positive pulmonary tuberculosis patients. Methods A retrospective analysis of 86 cases of retreatment smear positive pulmonary tuberculosis admitted to TB hospital of bone disease in Jilin Province from January 2012 to December 2013 was divided into study group and control group according to random number table method, with 43 cases in each group. Patients in the control group were given conventional antituberculous therapy while levofloxacin hydrochloride capsules were given. Patients in the study group were injected subcutaneously with thymosin on the basis of the control group. The therapeutic effect, the complete absorption rate of the lesions, the incidence of adverse reactions and the changes of T lymphocytes Subgroups. Results The total effective rate of treatment in study group was significantly higher than that in control group (P <0.05). The complete absorption rate of study group was significantly higher than that in control group (P <0.05) ; After treatment, the percentage of CD3 +, CD4 +, CD4 + / CD8 + T lymphocyte subsets in the study group was significantly higher than that in the control group, the percentage of CD8 + T lymphocyte subsets was significantly lower than that in the control group P <0.05). Conclusion Thymosin combined with anti-tuberculosis drugs in the treatment of relapsed smear-positive pulmonary tuberculosis clinical effect is obvious, can significantly improve the patient’s immune function, and less adverse reactions.